Treatment of the Childhood Haemolytic Uraemic Syndrome with Plasma. A Multicentre Randomized Controlled Trial. The French Society of Paediatric Nephrology

Overview

Journal Pediatr Nephrol

Specialties Nephrology
Pediatrics

Date 1988 Jul 1

PMID 3153025

Citations 26

Authors

C Loirat

E Sonsino

N HINGLAIS

J P Jais

P Landais

J Fermanian

Affiliations

Soon will be listed here.

Abstract

Seventy-nine children with haemolytic uraemic syndrome (mean age 28 months) were randomly assigned either to a group receiving plasma infusions (plasma group, n = 39) or to a group treated conservatively (control group, n = 40). The duration of haemolysis, thrombocytopenia and anuria was similar in the two groups. Serum creatinine levels were similar in the two groups at the 1-month follow-up but were higher in the control group at 3 months (plasma group 49 +/- 14, control group 66 +/- 28 mumol/l; P less than 0.02) and at 6 months (plasma group 48 +/- 13, control group 63 +/- 21 mumol/l; P less than 0.005). The prevalence of proteinuria was also higher in the control group at the 6-month follow-up (plasma group 17%, control group 46%; P less than 0.02). However, differences were no longer significant after 1 year. Renal tissue was examined in 54 cases (plasma group, n = 27; control group, n = 27). Diffuse cortical necrosis was present in 7 cases in the control group but was absent in the plasma group (P less than 0.02). Taking into consideration the higher serum creatinine levels, the higher prevalence of proteinuria during the first 6 months of follow-up in the control group and the presence of diffuse cortical necrosis in this group compared with the plasma group, we conclude that plasma infusions should be regarded as beneficial. Further study is needed to determine which plasma fraction is involved.

Citing Articles

Shiga Toxin-Associated Hemolytic Uremic Syndrome: Specificities of Adult Patients and Implications for Critical Care Management.

Travert B, Rafat C, Mariani P, Cointe A, Dossier A, Coppo P Toxins (Basel). 2021; 13(5).

PMID: 33925836 PMC: 8145702. DOI: 10.3390/toxins13050306.

Shiga Toxin-Associated Hemolytic Uremic Syndrome: A Narrative Review.

Joseph A, Cointe A, Mariani Kurkdjian P, Rafat C, Hertig A Toxins (Basel). 2020; 12(2).

PMID: 31973203 PMC: 7076748. DOI: 10.3390/toxins12020067.

Hemolytic uremic syndrome in a developing country: Consensus guidelines.

Bagga A, Khandelwal P, Mishra K, Thergaonkar R, Vasudevan A, Sharma J Pediatr Nephrol. 2019; 34(8):1465-1482.

PMID: 30989342 DOI: 10.1007/s00467-019-04233-7.

Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab.

Delmas Y, Vendrely B, Clouzeau B, Bachir H, Bui H, Lacraz A Nephrol Dial Transplant. 2013; 29(3):565-72.

PMID: 24293658 PMC: 3938298. DOI: 10.1093/ndt/gft470.

Principles of separation: indications and therapeutic targets for plasma exchange.

Williams M, Balogun R Clin J Am Soc Nephrol. 2013; 9(1):181-90.

PMID: 24178973 PMC: 3878701. DOI: 10.2215/CJN.04680513.

References

Schlegel N, Maclouf J, Loirat C, Drouet L, MAROTTE R, Scarabin P . Absence of plasma prostacyclin stimulating activity deficiency in hemolytic uremic syndrome. J Pediatr. 1987; 111(1):71-7. DOI: 10.1016/s0022-3476(87)80344-x. View

Chamone D, Proesmans W, Monnens L, Binda ki Muaka P, Vermylen J . Reversible deficient prostacyclin release in childhood hemolytic uremic syndrome. Int J Pediatr Nephrol. 1982; 3(1):13-6. View

Taylor C, White R, Winterborn M, Rowe B . Haemolytic-uraemic syndrome: clinical experience of an outbreak in the West Midlands. Br Med J (Clin Res Ed). 1986; 292(6534):1513-6. PMC: 1340507. DOI: 10.1136/bmj.292.6534.1513. View

Lian E, Harkness D, Byrnes J, WALLACH H, Nunez R . Presence of a platelet aggregating factor in the plasma of patients with thrombotic thrombocytopenic purpura (TTP) and its inhibition by normal plasma. Blood. 1979; 53(2):333-8. View

Byrnes J, Khurana M . Treatment of thrombotic thrombocytopenic purpura with plasma. N Engl J Med. 1977; 297(25):1386-9. DOI: 10.1056/NEJM197712222972507. View

Kelton J, Moore J, Santos A, Sheridan D . The detection of a platelet-agglutinating factor in thrombotic thrombocytopenic purpura. Ann Intern Med. 1984; 101(5):589-93. DOI: 10.7326/0003-4819-101-5-589. View

DENNEBERG T, Friedberg M, Holmberg L, Mathiasen C, Nilsson K, Takolander R . Combined plasmapheresis and hemodialysis treatment for severe hemolytic-uremic syndrome following Campylobacter colitis. Acta Paediatr Scand. 1982; 71(2):243-5. DOI: 10.1111/j.1651-2227.1982.tb09408.x. View

McLeod B, Wu K, Knospe W . Plasmapheresis in thrombotic thrombocytopenic purpura. Arch Intern Med. 1980; 140(8):1059-60. View

Turi S, Beattie T, Belch J, MURPHY A . Disturbances of prostacyclin metabolism in children with hemolytic-uremic syndrome and in first degree relatives. Clin Nephrol. 1986; 25(4):193-8. View

10.

Ansell J, Slepchuk Jr N, Pechet L . Platelet-aggregating factor in thrombotic thrombopenic purpura plasma. Blood. 1979; 54(4):959-60. View

11.

Trompeter R, Schwartz R, Chantler C, Dillon M, Haycock G, Kay R . Haemolytic-uraemic syndrome: an analysis of prognostic features. Arch Dis Child. 1983; 58(2):101-5. PMC: 1628096. DOI: 10.1136/adc.58.2.101. View

12.

Jorgensen K, Pedersen R . Familial deficiency of prostacyclin production stimulating factor in the hemolytic uremic syndrome of childhood. Thromb Res. 1981; 21(3):311-5. DOI: 10.1016/0049-3848(81)90168-7. View

13.

Loirat C, Sonsino E, Varga Moreno A, Pillion G, Mercier J, Beaufils F . Hemolytic-uremic syndrome: an analysis of the natural history and prognostic features. Acta Paediatr Scand. 1984; 73(4):505-14. DOI: 10.1111/j.1651-2227.1984.tb09962.x. View

14.

Misiani R, Appiani A, Edefonti A, Gotti E, Bettinelli A, Giani M . Haemolytic uraemic syndrome: therapeutic effect of plasma infusion. Br Med J (Clin Res Ed). 1982; 285(6351):1304-6. DOI: 10.1136/bmj.285.6351.1304. View

15.

Remuzzi G, Misiani R, Marchesi D, Livio M, MECCA G, de Gaetano G . Treatment of the hemolytic uremic syndrome with plasma. Clin Nephrol. 1979; 12(6):279-84. View

16.

Monnens L, van de Meer W, Langenhuysen C, van MUNSTER P, van Oostrom C . Platelet aggregating factor in the epidemic form of hemolytic-uremic syndrome in childhood. Clin Nephrol. 1985; 24(3):135-7. View

17.

Myers T, Wakem C, Ball E, Tremont S . Thrombotic thrombocytopenic purpura: combined treatment with plasmapheresis and antiplatelet agents. Ann Intern Med. 1980; 92(2 Pt 1):149-55. DOI: 10.7326/0003-4819-92-2-149. View

18.

Remuzzi G, Misiani R, Marchesi D, Livio M, MECCA G, de Gaetano G . Haemolytic-uraemic syndrome: deficiency of plasma factor(s) regulating prostacyclin activity?. Lancet. 1978; 2(8095):871-2. DOI: 10.1016/s0140-6736(78)91573-8. View

19.

Fong J, de Chadarevian J, Kaplan B . Hemolytic-uremic syndrome. Current concepts and management. Pediatr Clin North Am. 1982; 29(4):835-56. DOI: 10.1016/s0031-3955(16)34216-x. View

20.

Beattie T, MURPHY A, WILLOUGHBY M, Machin S, Defreyn G . Plasmapheresis in the haemolytic-uraemic syndrome in children. Br Med J (Clin Res Ed). 1981; 282(6277):1667-8. PMC: 1505665. DOI: 10.1136/bmj.282.6277.1667. View